Any abnormal value that persists should be followed at the discretion of the investig ator. 6.7.8 Clinical Laboratory Parameters 6.7.8.1 Hematology and Clinical Chemistry The hematology panel will consist of complete blood count (hemoglobin, hematocrit, erythrocytes [i.e., red blood cell count], and leukocytes [i.e., white blood cell count]) with differential (i.e., basophils, eosinophils, lymphocytes, monocytes, neutrophils) and platelet counts. The clinical chemistry panel will consist of sodium, potassium, chloride, bicarbonate, protein, albumin, ALAT , ASAT, gamma- glutamyl transpeptidase, total bilirubin, uric acid, blood urea nitrogen, creatinine, lactate dehydrogenase, creatine phosphokinase, alkaline phosphatase and glucose. Urinalysis will include description of color and clarity, specific gravity, pH, content of protein, glucose, nitrites and ketones. A microscopic analysis will be performed to check for red or white blood cells, casts, crystals, bacteria, yeast cells, parasites , and squamous cells. Urine and blood samples will be obtained for assessment of hematology and clinical chemistry at Screening, at Visit 2 (Day 1, Week 0) , Visit 4 (Week 6) , Visit 6 (Week 12), Visit 9 (Week 19), Visit 11 (Week 25), Visit 14 (Week 32) and Visit 16 (Week 38). Hematology and clinical chemistry assessments will be performed at the local laboratory at the investigator site. 6.7.8.2 Tumor Biomarke rs Blood samples will be collected to evaluate tumor biomarkers, including carcinoembryonic antigen (CEA) and cancer antigen (CA 19-9). Treos Bio ZRT OBERTO -101 Amendment 3 Product: PolyPEPI 1018 Colorectal Cancer Vaccine Page 54 of 81 CONFIDENTIAL 6.7.8.3 Assessment of Laboratory Values 6.7.8.3.1 Assessment of Abnormal Laboratory Values The investigator’s assessment of each laboratory value will be recorded on the CRF. For each abnormal laboratory value, the investigator will determine whether the value is considered clinically significant or not.